ArticleAnnals of medicine2026
The multiple composite risk index estimates the risks of sarcopenia and comorbidities: unveiling the role of oxidative balance score.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity, purine metabolism disorders, and dyslipidemia are recognized risk factors for sarcopenia, yet reliable biomarkers for risk stratification in this population are lacking. We integrated the uric acid to high-density lipoprotein cholesterol ratio (UHR) with the body roundness index (BRI) to construct a multiple composite risk index, UHR-BRI, and evaluated its associations with sarcopenia and its comorbidities.
methodsWe analyzed two nationally representative cohorts: the China Health and Retirement Longitudinal Study (CHARLS) and the National Health and Nutrition Examination Survey (NHANES). The association between UHR-BRI and sarcopenia was evaluated using weighted logistic regression. Subgroup and mediation analyses were performed to investigate the interactions across subgroups, and the mediating role of oxidative balance score (OBS).
resultsA total of 8,537 participants from CHARLS and 8,510 from NHANES were included, among whom 1,082 and 716 were diagnosed with sarcopenia. The area under the curve (AUC) value of the UHR-BRI index was higher than that of the other indices in both cohorts. In fully adjusted models, participants in the highest UHR-BRI quartile exhibited a significantly increased risk of sarcopenia (OR:3.01, 95% CI:2.45-3.72) compared to those in the lowest quartile in CHARLS. This finding was validated in NHANES (OR:17.14, 95% CI:11.55-26.60). Subgroup analyses further demonstrated robustness across different subgroups. Furthermore, UHR-BRI was also significantly associated with sarcopenia comorbidities. Mediation analyses confirmed that OBS mediated the associations between UHR-BRI and sarcopenia and its comorbidities.
conclusionUHR-BRI is significantly associated with sarcopenia and its common comorbidities, and OBS was identified as a potential mediator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.